“Confident in Usefulness” of Alogliptin: President Hasegawa of Takeda

Yasuchika Hasegawa, president and CEO, Takeda Pharmaceutical, stressed at a business briefing on May 11 that there is no change to the fact that we remain confident in the usefulness of the DPP-4 inhibitor alogliptin (development code: SYR-322) for which...read more